By Neena Bhandari

Sydney, 28.08.2025 (Oncology Republic): Overall survival benefit is compelling enough to consider talazoparib and enzalutamide combination as standard first line therapy in patients with metastatic castration-resistant prostate cancer and mutations in the homologous recombination repair genes, particularly those with BRCA1 and BRCA2 gene mutations, researchers say.

Their findings from the final analysis from the TALAPRO-2 trial have been recently published in The Lancet. Talazoparib plus enzalutamide combination significantly improved OS compared with enzalutamide plus placebo (HR 0·62 [95% CI 0·48–0·81, p=0.0005) in patients with HRR-deficient mCRPC. The median OS was 45.1 months with the combination versus 31.1 months with enzalutamide alone.

Professor Arun Azad, co-author of the study, and medical oncologist at Peter MacCallum Cancer Centre said the findings were important. “The data from this trial shows that there’s a statistically significant and also clinically meaningful improvement in survival and quality of life for patients using this combination, as opposed to enzalutamide alone, which is the standard of care,” he said.

Continue Reading on Oncology Republic

© Copyright Neena Bhandari. All rights reserved. Republication, copying or using information from neenabhandari.com content is expressly prohibited without the permission of the writer and the media outlet syndicating or publishing the article.